November Monthly Report

Last month my portfolio beat the wider market by circa. 2%, this month we smashed it out of the ballpark by recording a gain of 9.32%. Given the XJO retreated by 4.16% during the month, this means the portfolio outperformed by a very impressive 13.48% (even with 45% of the portfolio in cash).

Market:	Close October	Close October	Percentage Change:
XJO	4298	4119	-4.16%
XSO	2407	2315	-3.82%

After such a strong October it was highly likely that November would be a weak month, and it was. The ASX 200 (XJO) closed down 4.16%, with the Small Ords (XSO) fairing a little better at 3.82%. This seems to indicate that traders and investors are still happy holding the “riskier stocks” which can only be a positive in my opinion.

Code:	Weighting:	Share Price End of October	Share Price End of November	Percentage Change:	Weighted Change:
OBJ	23.11%	0.022	0.021	-4.55%	-1.05%
MHM	7.28%	0.740	1.035	39.86%	2.90%
KGL	23.84%	0.099	0.130	31.31%	7.47%
Cash	45.77%			0%	0.00%
TOTAL				22.211%	9.32%

In regard to the individual stocks it is hard to go past MHM who rocketed up 39.86%. This was on the back of three supply contracts for their new US plant and confirmation of a press conference that is taking place early next week. Unfortunately for me, and the portfolios performance, MHM only represents 7.28% of the portfolio which means on a weighted basis that 39.86% gain gets watered down to only 2.90%.

Kentor Gold was the other strong performer up 31.31%. This was not really on the back of any news, just general improved sentiment towards the stock and a build-up of anticipation as news on Andash fast approaches.

OBJ was the poor performer and closed down 5%. Not a great deal to worry about, but it did give up some of its intra-month highs relatively easy. As with all bio-tech’s though it is a waiting game and until you get a solid announcement nothing too much happens.

Code:	Weighting:	Share Price End of October	Share Price End of November	Percentage Change:	Weighted Change:
OBJ	42.61%	0.022	0.021	-4.55%	-1.94%
MHM	13.43%	0.740	1.035	39.86%	5.35%
KGL	43.96%	0.099	0.130	31.31%	13.77%
TOTAL					17.18%

Removing cash from the equation shows a very healthy 17.18% return for the month. On this basis the portfolio outperformed the broader market by over 20%. We do however have to consider that both OBJ and MHM remain slightly underwater compared to my original purchase prices, but at least MHM appears to be heading in the right direction.